Association between the efcacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: A retrospective study
Số trang: 10
Loại file: pdf
Dung lượng: 1.19 MB
Lượt xem: 6
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The combination of immune-checkpoint inhibitors with chemotherapy has become the standard of treatment for non-small cell lung cancer (NSCLC) patients. However, the association between therapeutic efcacy and the development of immune-related adverse events (irAEs) remains unclear in patients treated with combination therapy.
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Non‐small cell lung cancer Immune-checkpoint inhibitors Combination therapy Immune-related adverse eventsTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
13 trang 38 0 0